Anti-thymocyte globulin (rabbit) is under clinical development by Neovii Pharmaceuticals and currently in Phase III for Myelodysplastic Syndrome. According to GlobalData, Phase III drugs for Myelodysplastic Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Anti-thymocyte globulin (rabbit)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-thymocyte globulin (rabbit) overview
Anti-thymocyte globulin (Rabbit) (ATG, Grafalon, EZ-2053) is a polyclonal antibody. It is formulated as concentrate solution for injection, administered through intravenous route of administration. Anti-thymocyte globulin is indicated in combination with other immunosuppressive drugs to suppress the competent immune cells that are the cause of acute rejection in kidney transplant patients or of graft versus host disease, indicated in combination with other immunosuppressive drugs (eg, glucocorticosteroids, purine antagonists, calcineurin inhibitors and mTOR inhibitors), to reinforce immunosuppression preoperatively, perioperative or postoperative immediately after renal transplantation, treatment of acute rejection resistant to corticosteroids after renal transplantation if methylprednisolone therapy has proved unsatisfactory, for the prevention of graft versus host disease (GVHD) in adults with a pattern of myeloablative conditioning prior to hematopoietic stem cells from peripheral blood or bone marrow of matched unrelated donor, in combination with usual prophylaxis using cyclosporin A/methotrexate.
It is under development for the prevention of moderate to severe chronic GVHD, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). It was also under development for the prophylaxis of acute pulmonary allograft rejection.
Neovii Pharmaceuticals overview
Neovii Pharmaceuticals is a biopharmaceutical business with a patient-centered objective to create and commercialise innovative, life-changing treatments to enhance outcomes in hemato-oncology, immunological diseases, and transplantation medicine. The company is headquartered in Switzerland.
For a complete picture of Anti-thymocyte globulin (rabbit)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
